Financials data is unavailable for this security.
View more
Year on year Pacira Biosciences Inc had relatively flat revenues (666.82m to 674.98m), though the company grew net income 163.72% from 15.91m to 41.96m.
Gross margin | 74.35% |
---|---|
Net profit margin | -13.06% |
Operating margin | -8.26% |
Return on assets | -5.94% |
---|---|
Return on equity | -11.48% |
Return on investment | -6.83% |
More ▼
Cash flow in USDView more
In 2023, Pacira Biosciences Inc increased its cash reserves by 47.21%, or 49.16m. The company earned 154.65m from its operations for a Cash Flow Margin of 22.91%. In addition the company generated 77.54m cash from investing, though they paid out 183.03m more in financing than they received.
Cash flow per share | -0.2734 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 16.24 |
---|---|
Tangible book value per share | 6.70 |
More ▼
Balance sheet in USDView more
Current ratio | 2.25 |
---|---|
Quick ratio | 1.89 |
Total debt/total equity | 0.7836 |
---|---|
Total debt/total capital | 0.4393 |
More ▼